Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MOGAT2 | Q3SYC2 | 7/20 | 0.44 |
| ▸ | PRF1 | P14222 | 1/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 6/20 | 0.42 |
| ▸ | MGAT3 | Q09327 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15091833 | 0.80 | CA1 (0.49) | LMNAMOGAT2CA1CA2CA9 | |
| SCHEMBL9952995 | 0.80 | LMNA (0.49) | LMNAPIK3C3PIK3CACA1CA2 | |
| SCHEMBL462147 | 0.79 | PIK3CB (0.55) | PIK3CAPRF1 | |
| SCHEMBL9953720 | 0.78 | ALPL (0.62) | PIK3C3PIK3CA | |
| SCHEMBL15092126 | 0.77 | AXL (0.45) | LMNAMOGAT2MGAT2MGAT3CA1 | |
| SCHEMBL14247351 | 0.77 | CA1 (0.39) | CA1CA2CA9 | |
| SCHEMBL9953341 | 0.77 | ALPL (0.51) | LMNAPIK3CATSHRHSD17B10 | |
| SCHEMBL30720423 | 0.76 | AXL (0.44) | LMNAMOGAT2CA1CA2CA9 | |
| SCHEMBL790655 | 0.75 | PIK3C3 (0.53) | PIK3C3PIK3CA | |
| SCHEMBL3109727 | 0.74 | LMNA (0.59) | LMNAPIK3C3PIK3CAMOGAT2PRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011121317-A1 | IMIDAZO [2,1-B] [1,3,4] THIADIAZOLES AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-10-06 | — | — | WO | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | LMNA 3236/4885PIK3C3 19/4885PIK3CA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.